Literature DB >> 18391615

Surgical resection of hepatocellular carcinoma.

John P Duffy1, Jonathan R Hiatt, Ronald W Busuttil.   

Abstract

The incidence of hepatocellular carcinoma (HCC) is increasing in the United States, primarily due to hepatitis C-related liver disease. Nearly 85%-90% of patients with HCC have underlying chronic liver disease or cirrhosis. Advanced tumor burden or prohibitive hepatic dysfunction precludes operative resection in most patients with HCC. Surgical resection is a treatment option with curative intent in patients with HCC not associated with cirrhosis or in patients with well-compensated liver disease. Tumor extent and hepatic function must be assessed preoperatively to avoid postresection hepatic failure, an often fatal condition that may require urgent liver transplantation. Appropriately selected candidates for liver resection have 5-year postoperative survival rates of 40%-70%, but recurrence rates approach 70%, especially in patients with cirrhosis. For this reason, the best resection for patients with HCC and cirrhosis is orthotopic liver transplantation, which has 5-year posttransplant survival rates of 65%-80% in well-selected candidates.

Entities:  

Mesh:

Year:  2008        PMID: 18391615     DOI: 10.1097/PPO.0b013e31816a5c1f

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  18 in total

1.  Surgical vs percutaneous radiofrequency ablation for hepatocellular carcinoma in dangerous locations.

Authors:  Ji-Wei Huang; Roberto Hernandez-Alejandro; Kristopher P Croome; Lu-Nan Yan; Hong Wu; Zhe-Yu Chen; Pankaj Prasoon; Yong Zeng
Journal:  World J Gastroenterol       Date:  2011-01-07       Impact factor: 5.742

Review 2.  Efficacy and safety of percutaneous radiofrequency ablation versus surgical resection for small hepatocellular carcinoma: a meta-analysis of 23 studies.

Authors:  Qian Feng; Yugang Chi; Yanqian Liu; Ling Zhang; Qi Liu
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-03       Impact factor: 4.553

3.  Paris saponin H suppresses human hepatocellular carcinoma (HCC) by inactivation of Wnt/β-catenin pathway in vitro and in vivo.

Authors:  Tiezhu Chen; Juan Lin; Daxuan Tang; Mei Zhang; Feiyan Wen; Dan Xue; Hao Zhang
Journal:  Int J Clin Exp Pathol       Date:  2019-08-01

Review 4.  Reappraisal of evidence of microscopic portal vein involvement by hepatocellular carcinoma cells with stratification of tumor size.

Authors:  Yuesi Zhong; Meihai Deng; Ruiyun Xu
Journal:  World J Surg       Date:  2015-05       Impact factor: 3.352

5.  Gut-liver axis improves with meloxicam treatment after cirrhotic liver resection.

Authors:  Astrit R Hamza; Avdyl S Krasniqi; Pramod Kadaba Srinivasan; Mamdouh Afify; Christian Bleilevens; Uwe Klinge; René H Tolba
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

6.  Hepatic resection for large hepatocellular carcinoma in the era of UCSF criteria.

Authors:  Spiros G Delis; Andreas Bakoyiannis; Nikos Tassopoulos; Kostas Athanassiou; Aristotelis Kechagias; Dimitrios Kelekis; Juan Madariaga; Christos Dervenis
Journal:  HPB (Oxford)       Date:  2009-11       Impact factor: 3.647

7.  Efficiency and safety of radiofrequency-assisted hepatectomy for hepatocellular carcinoma with cirrhosis: A single-center retrospective cohort study.

Authors:  Fan Zhang; Jun Yan; Xiao-Bin Feng; Feng Xia; Xiao-Wu Li; Kuan-Sheng Ma; Ping Bie
Journal:  World J Gastroenterol       Date:  2015-09-21       Impact factor: 5.742

8.  Safe hepatectomy selection criteria for hepatocellular carcinoma patients: a validation of 336 consecutive hepatectomies. The BILCHE score.

Authors:  Matteo Donadon; Guido Costa; Matteo Cimino; Fabio Procopio; Daniele Del Fabbro; Angela Palmisano; Guido Torzilli
Journal:  World J Surg       Date:  2015-01       Impact factor: 3.352

Review 9.  Value of radiofrequency ablation in the treatment of hepatocellular carcinoma.

Authors:  Kai Feng; Kuan-Sheng Ma
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

10.  Tumor factors associated with clinical outcomes in patients with hepatitis B virus infection and hepatocellular carcinoma.

Authors:  Myron John Tong; Surachate Siripongsakun; Gaelen Stanford-Moore; Leeyen Hsu; Patrick Weijen Chang; Lawrence Mitchell Blatt
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.